Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...
Pfizer shares are trading in the mid-$20s as investors grapple with a critical question: is this battered pharmaceutical giant destined to remain stuck in neutral, or does its aggressive push into ...
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results